Stockreport

QIAGEN Launches Therascreen BRAF Test as Companion Diagnostic to a BRAFTOVI® (encorafenib) Based Regimen in Metastatic Colorectal Cancer

Qiagen N.V. Common Shares  (QGEN) 
Last qiagen n.v. common shares earnings: 2/4 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: corporate.qiagen.com/investor-relations
PDF U.S. FDA approves therascreen BRAF V600E RGQ PCR assay as companion diagnosticTest will help identify patients eligible for treatment with the BRAF inhibitor, BRAFTOVI, [Read more]